Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 2, 2009, Pages 128-143

  Ghochikyan, Anahit ^a  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

Author keywords

Alzheimer's Disease; DNA vaccine; Epitope vaccine; Immunotherapy; Peptide vaccine

Indexed keywords

ACC 001; ALUMINUM POTASSIUM SULFATE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-11] MACROPHAGE DERIVED CHEMOKINE PAN HUMAN LEUKOCYTE ANTIGEN DR BINDING PROTEIN DNA EPITOPE VACCINE; AMYLOID BETA PROTEIN[1-15] MULTIPLE ANTIGENIC PEPTIDE PAN HUMAN LEUKOCYTE ANTIGEN DR BINDING PROTEIN DNA EPITOPE VACCINE; AMYLOID BETA PROTEIN[1-15] PAN HUMAN LEUKOCYTE ANTIGEN DR BINDING PROTEIN DNA EPITOPE VACCINE; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-7] DIPHTHERIA TOXOID CRM197 CONJUGATE; CAD 106; DNA VACCINE; EPITOPE; PEPTIDE VACCINE; PLACEBO; QS 21; UNCLASSIFIED DRUG; DNA; PEPTIDE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ASTROCYTOSIS; B LYMPHOCYTE; BEHAVIOR DISORDER; BRAIN HEMORRHAGE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL STUDY; CLINICAL TRIAL; DNA IMMUNIZATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EPITOPE MAPPING; HUMAN; IMMUNOTHERAPY; LYMPHOCYTIC INFILTRATION; MENINGOENCEPHALITIS; NERVE CELL DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PASSIVE IMMUNIZATION; REVIEW; SENILE PLAQUE; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINE PRODUCTION; VASCULAR AMYLOIDOSIS; VASCULITIS; VIRUS LIKE AGENT; ACTIVE IMMUNIZATION; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; STANDARD; STATISTICS;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; CLINICAL TRIALS AS TOPIC; DNA; EPITOPES; HUMANS; IMMUNOTHERAPY, ACTIVE; PEPTIDES; TREATMENT OUTCOME;

EID: 67649635732     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709787847298     Document Type: Review

References (108)

1. Ziegler-Graham, K.; Brookmeyer, R.; Johnson, E.; Arrighi, H.M.; Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement., 2008, 4, 316-23.
2. Price, D.L.; Sisodia, S.S. Cellular and molecular biology of Alzheimer's disease and animal models. Annu. Rev. Med., 1994, 45, 435-46.
3. Campion, D.; Dumanchin, C.; Hannequin, D.; Dubois, B.; Belliard, S.; Puel, M.; Thomas-Anterion, C.; Michon, A.; Martin, C.; Charbonnier, F.; Raux, G.; Camuzat, A.; Penet, C.; Mesnage, V.; Martinez, M.; Clerget-Darpoux, F.; Brice, A.; Frebourg, T. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am. J. Hum. Genet., 1999, 65, 664-70.
4. Iqbal, K.; Grundke-Iqbal, I. Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J. Cell. Mol. Med., 2008, 12, 38-55.
5. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297, 353-6.
6. Hardy, J.A.; Higgins, G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992, 256, 184-5.
7. Selkoe, D.J. The molecular pathology of Alzheimer's disease. Neuron, 1991; 6: 487-98.
8. Selkoe, D.J. Alzheimer's disease: a central role for amyloid. J. Neuropathol. Exp. Neurol., 1994, 53, 438-47.
9. Esler, W.P.; Wolfe, M.S. A portrait of Alzheimer secretases-new features and familiar faces. Science, 2001, 293, 1449-54.
10. Kamenetz, F.; Tomita, T.; Hsieh, H.; Seabrook, G.; Borchelt, D.; Iwatsubo, T.; Sisodia, S.; Malinow, R. APP processing and synaptic function. Neuron, 2003, 37, 925-37.
11. Paresce, D.M.; Chung, H.; Maxfield, F.R. Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells. J. Biol. Chem., 1997, 272, 29390-7.
12. Qiu, W.Q.; Ye, Z.; Kholodenko, D.; Seubert, P.; Selkoe, D.J. Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J. Biol. Chem., 1997, 272, 6641-6.
13. Iwata, N.; Tsubuki, S.; Takaki, Y.; Watanabe, K.; Sekiguchi, M.; Hosoki, E.; Kawashima-Morishima, M.; Lee, H.J.; Hama, E.; Sekine-Aizawa, Y.; Saido, T.C. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med., 2000, 6, 143-50.
14. Qiu, W.Q.; Walsh, D.M.; Ye, Z.; Vekrellis, K.; Zhang, J.; Podlisny, M.B.; Rosner, M.R.; Safavi, A.; Hersh, L.B.; Selkoe, D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem., 1998, 273, 32730-8.
15. Shibata, M.; Yamada, S.; Kumar, S.R.; Calero, M.; Bading, J.; Frangione, B.; Holtzman, D.M.; Miller, C.A.; Strickland, D.K.; Ghiso, J.; Zlokovic, B.V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest., 2000, 106, 1489-99.
16. Schley, D.; Carare-Nnadi, R.; Please, C.P.; Perry, V.H.; Weller, R.O. Mechanisms to explain the reverse perivascular transport of solutes out of the brain. J. Theor. Biol., 2006, 238, 962-74.
17. Weller, R.O.; Massey, A.; Newman, T.A.; Hutchings, M.; Kuo, Y.M.; Roher, A.E. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am. J. Pathol., 1998, 153, 725-33.
18. Du, Y.; Dodel, R.; Hampel, H.; Buerger, K.; Lin, S.; Eastwood, B.; Bales, K.; Gao, F.; Moeller, H.J.; Oertel, W.; Farlow, M.; Paul, S. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology, 2001, 57, 801-5.
19. Moir, R.D.; Tseitlin, K.A.; Soscia, S.; Hyman BT, Irizarry MC, Tanzi RE. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J. Biol. Chem., 2005, 280, 17458-63.
20. Weksler, M.E.; Relkin, N.; Turkenich, R.; LaRusse, S.; Zhou, L.; Szabo, P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol., 2002, 37, 943-8.
21. Morgan, D.; Diamond, D.M.; Gottschall, P.E.; Ugen, K.E.; Dickey, C.; Hardy, J.; Duff, K.; Jantzen, P.; Di-Carlo, G.; Wilcock, D.; Connor, K.; Hatcher, J.; Hope, C.; Gordon, M.; Arendash, G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000, 408, 982-5.
22. Janus, C.; Pearson, J.; McLaurin, J.; Mathews, P.M.; Jiang, Y.; Schmidt, S.D.; Chishti, M.A.; Horne, P.; Heslin, D.; French, J.; Mount, H.T.; Nixon, R.A.; Mercken, M.; Bergeron, C.; Fraser, P.E.; St. George-Hyslop, P.; Westaway, D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 2000, 408, 979-82.
23. Bard, F.; Cannon, C.; Barbour, R.; Burke, R.L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Lieberburg, I.; Motter, R.; Nguyen, M.; Soriano, F.; Vasquez, N.; Weiss, K.; Welch, B.; Seubert, P.; Schenk, D.; Yednock, T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med., 2000, 6, 916-9.
24. Dodart, J.C.; Bales, K.R.; Gannon, K.S.; Greene, S.J.; DeMattos, R.B.; Mathis, C.; DeLong, C.A.; Wu, S.; Wu, X.; Holtzman, D.M.; Paul, S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci., 2002, 5, 452-7.
25. Kotilinek, L.A.; Bacskai, B.; Westerman, M.; Kawarabayashi, T.; Younkin, L.; Hyman, B.T.; Younkin, S.; Ashe, K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci., 2002, 22, 6331-5.
26. Wilcock, D.M.; Rojiani, A.; Rosenthal, A.; Levkowitz, G.; Subbarao, S.; Alamed, J.; Wilson, D.; Wilson, N.; Freeman, M.J.; Gordon, M.N.; Morgan, D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci., 2004, 24, 6144-51.
27. Wilcock, D.M.; Rojiani, A.; Rosenthal, A.; Subbarao, S.; Freeman, M.J.; Gordon, M.N.; Morgan, D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation, 2004, 1, 24.
28. Pfeifer, M.; Boncristiano, S.; Bondolfi, L.; Stalder, A.; Deller, T.; Staufenbiel, M.; Mathews, P.M.; Jucker, M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science, 2002, 298, 1379.
29. DeMattos, R.B.; Boone, L.I.; Hepburn, D.L.; Parsadanian, M.; Bryan, M.T.; Ness, D.K.; Piroozi, K.S.; Holtzman, D.M.; Bales, K.R.; Gitter, B.D.; Paul, S.M.; Racke, M. In vitro and in vivo characterization of beta-amyloid antibodies binding to cerebral amyloid angiopathy (CAA) and the selective exacerbation of CAA-associated microhemorrhage. Neurobiol. Aging, 2004, 25, 577.
30. Wilcock, D.M.; Alamed, J.; Gottschall, P.E.; Grimm, J.; Rosenthal, A.; Pons, J.; Ronan, V.; Symmonds, K.; Gordon, M.N.; Morgan, D. Deglycosylated antiamyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J. Neurosci., 2006, 26, 5340-6.
31. Wilcock, D.M.; Jantzen, P.T.; Li, Q.; Morgan, D.; Gordon, M.N. Amyloid-b vaccination, but not nitro-NSAID treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience, 2007, 144, 950-60.
32. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; Zotova, E.; Nicoll, J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 2008, 372, 216-23.
33. Gilman, S.; Koller, M.; Black, R.S.; Jenkins, L.; Griffith, S.G.; Fox, N.C.; Eisner, L.; Kirby, L.; Rovira, M.B.; Forette, F.; Orgogozo, J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 2005, 64, 1553-62.
34. Hock, C.; Konietzko, U.; Streffer, J.R.; Tracy, J.; Signorell, A.; Muller-Tillmanns, B.; Lemke, U.; Henke, K.; Moritz, E.; Garcia, E.; Wollmer, M.A.; Umbricht, D.; de Quervain, D.J.; Hofmann, M.; Maddalena, A.; Papassotiropoulos, A.; Nitsch, R.M. Antibodies against beta-Amyloid slow cognitive decline in Alzheimer's disease. Neuron, 2003, 38, 547-54.
35. Nicoll, J.A.; Wilkinson, D.; Holmes, C.; Steart, P.; Markham, H.; Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med., 2003, 9, 448-52.
36. Ferrer, I.; Rovira, M.B.; Guerra, M.L.S.; Rey, M.J.; Costa-Jussa, F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol., 2004, 14, 11-20.
37. Masliah, E.; Hansen, L.; Adame, A.; Crews, L.; Bard, F.; Lee, C.; Seubert, P.; Games, D.; Kirby, L.; Schenk, D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology, 2005, 64, 129-31.
38. Patton, R.L.; Kalback, W.M.; Esh, C.L.; Kokjohn, T.A.; Van Vickle, G.D.; Luehrs, D.C.; Kuo, Y.M.; Lopez, J.; Brune, D.; Ferrer, I.; Masliah, E.; Newel, A.J.; Beach, T.G.; Castano, E.M.; Roher, A.E. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am. J. Pathol., 2006, 169, 1048-63.
39. Nitsch, R.M.; Hock, C. Immunotherapy against beta-amyloid in Alzheimer's disease; 8th International Conference on Alzheimer's and Parkinson's disease: progress and new perspectives. Salzburg: Austria, 2007.
40. Boche, D.; DeBeer, S.; Cox, A.; Wilkinson, D.; Holmes, C.; Neal, J.; Love, S.; Esiri, M.; Bridges, L.; Weller, R.; Nicoll, J.A. Evidence of a transient increase in cerebral amyloid angiopathy after Abeta42 immunization in human Alzheimer's disease, 8th International Conference on Alzheimer's and Parkinson's disease: progress and new perspectives. Salzburg: Austria, 2007.
41. Nicoll, J.A.; Barton, E.; Boche, D.; Neal, J.W.; Ferrer, I.; Thompson, P.; Vlachouli, C.; Wilkinson, D.; Bayer, A.; Games, D.; Seubert, P.; Schenk, D.; Holmes, C. Abeta species removal after abeta42 immunization. J. Neuropathol. Exp. Neurol., 2006, 65, 1040-8.
42. Orgogozo, J.M.; Gilman, S.; Dartigues, J.M.; Laurent, B.; Puel, M.; Kirby, L.C.; Jouanny, P.; Dubois, B.; Eisner, L.; Flitman, S.; Michel, B.F.; Boada, M.; Frank, A.; Hock, C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 2003, 61(1), 46-54.
43. Bayer, A.J.; Bullock, R.; Jones, R.W.; Wilkinson, D.; Paterson, K.R.; Jenkins, L.; Millais, S.B.; Donoghue, S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology, 2005, 64, 94-101.
44. Fagan, A.M.; Roe, C.M.; Xiong, C.; Mintun, M.A.; Morris, J.C.; Holtzman, D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol., 2007, 64, 343-9.
45. Fagan, A.M.; Roe, C.M.; Xiong, C.; Mintun, M.A.; Morris, J.C.; Holtzman, D.M. Cerebrospinal fluid biomarkers of early stage Alzheimer disease, 8th International Conference on Alzheimer's and Parkinson's disease: progress and new perspectives. Salzburg: Austria, 2007.
46. de Jong, D.; Jansen, R.W.; Kremer, B.P.; Verbeek, M.M. Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. J. Gerontol. A Biol. Sci. Med. Sci., 2006, 61, 755-8.
47. Klunk, W.E.; Engler, H.; Nordberg, A.; Wang, Y.; Blomqvist, G.; Holt, D.P.; Bergstrom, M.; Savitcheva, I.; Huang, G.F.; Estrada, S.; Ausen, B.; Debnath, M.L.; Barletta, J.; Price, J.C.; Sandell, J.; Lopresti, B.J.; Wall, A.; Koivisto, P.; Antoni, G.; Mathis, C.A.; Langstrom, B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol., 2004, 55, 306-19.
48. Neumann, H. Control of glial immune function by neurons. Glia, 2001, 36, 191-9.
49. Hanisch, U.K. Microglia as a source and target of cytokines. Glia, 2002, 40, 140-55.
50. Yang, M.S.; Park, E.J.; Sohn, S.; Kwon, H.J.; Shin, W.H.; Pyo, H.K.; Jin, B.; Choi, K.S.; Jou, I.; Joe, E.H. Interleukin-13 and -4 induce death of activated microglia. Glia, 2002, 38, 273-80.
51. Shin, W.H.; Lee, D.Y.; Park, K.W.; Kim, S.U.; Yang, M.S.; Joe, E.H.; Jin, B.K. Microglia expressing interleukin-13 undergo cell death and contribute to neuronal survival in vivo. Glia, 2004, 46, 142-52.
52. Monsonego, A.; Imitola, J.; Zota, V.; Oida, T.; Weiner, H.L. Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid beta-peptide presentation to Th1 cells. J. Immunol., 2003, 171(5), 2216-24.
53. Yamamoto, M.; Kiyota, T.; Walsh, S.M.; Liu, J.; Kipnis, J.; Ikezu, T. Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. J. Immunol., 2008, 181, 3877-86.
54. Town, T.; Tan, J.; Sansone, N.; Obregon, D.; Klein, T.; Mullan, M. Characterization of murine immunoglobulin G antibodies agaisnt human amyloid-b 1-42. Neurosci. Lett., 2001, 307, 101-4.
55. Dickey, C.A.; Morgan, D.G.; Kudchodkar, S.; Weiner, D.B.; Bai, Y.; Cao, C.; Gordon, M.N.; Ugen, K.E. Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide. DNA Cell Biol., 2001, 20, 723-9.
56. Lemere, C.A.; Maron, R.; Selkoe, D.J.; Weiner, H.L. Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol., 2001, 20, 705-11.
57. Lemere, C.A.; Maron, R.; Spooner, E.T.; Grenfell, T.J.; Mori, C.; Desai, R.; Hancock, W.W.; Weiner, H.L.; Selkoe, D.J. Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP Mice. Ann. NY Acad Sci., 2000, 920, 328-31.
58. Cribbs, D.H.; Ghochikyan, A.; Tran, M.; Vasilevko, V.; Petrushina, I.; Sadzikava, N.; Kesslak, P.; Kieber-Emmons, T.; Cotman, C.W.; Agadjanyan, M.G. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol., 2003, 15, 505-14.
59. McLaurin, J.; Cecal, R.; Kierstead, M.E.; Tian, X.; Phinney, A.L.; Manea, M.; French, J.E.; Lambermon, M.H.; Darabie, A.A.; Brown, M.E.; Janus, C.; Chishti, M.A.; Horne, P.; Westaway, D.; Fraser, P.E.; Mount, H.T.; Przybylski, M.; St. George-Hyslop, P. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med., 2002, 8, 1263-9.
60. Solomon, B.; Koppel, R.; Hanan, E.; Katzav, T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc. Natl. Acad. Sci. USA, 1996, 93, 452-5.
61. Solomon, B.; Koppel, R.; Frankel, D.; Hanan-Aharon, E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA, 1997, 94, 4109-12.
62. Frenkel, D.; Balass, M.; Katchalski-Katzir, E.; Solomon, B. High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation. J. Neuroimmunol., 1999, 95, 136-42.
63. Mamikonyan, G.; Necula, M.; Mkrtichyan, M.; Ghochikyan, A.; Petrushina, I.; Movsesyan, N.; Mina, E.; Kiyatkin, A.; Glabe, C.; Cribbs, D.H.; Agadjanyan, M.G. Anti-Abeta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils, but not the most toxic oligomers. J. Biol. Chem., 2007, 282, 22376-86.
64. Bard, F.; Barbour, R.; Cannon, C.; Carretto, R.; Fox, M.; Games, D.; Guido, T.; Hoenow, K.; Hu, K.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, C.; Lee, M.; Motter, R.; Nguyen, M.; Reed, A.; Schenk, D.; Tang, P.; Vasquez, N.; Seubert, P.; Yednock, T. Epitope and isotype specificities of antibodies to beta - amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. USA, 2003, 100, 2023-8.
65. Miller, D.L.; Currie, J.R.; Mehta, P.D.; Potemska, A.; Hwang, Y.W.; Wegiel, J. Humoral immune response to fibrillar beta-amyloid peptide. Biochemistry, 2003, 42(40), 11682-92.
66. Lee, M.; Bard, F.; Johnson-Wood, K.; Lee, C.; Hu, K.; Griffith, S.G.; Black, R.S.; Schenk, D.; Seubert, P. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann. Neurol., 2005, 58, 430-5.
67. Sigurdsson, E.M.; Knudsen, E.; Asuni, A.; Fitzer-Attas, C.; Sage, D.; Quartermain, D.; Goni, F.; Frangione, B.; Wisniewski, T. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J. Neurosci., 2004, 24, 6277-82.
68. Singh, H.; Raghava, G.P. ProPred: prediction of HLA-DR binding sites. Bioinformatics, 2001, 17, 1236-7.
69. Singh, H.; Raghava, G.P. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics, 2003, 19, 1009-14.
70. Monsonego, A.; Zota, V.; Karni, A.; Krieger, J.I.; Bar-Or, A.; Bitan, G.; Budson, A.E.; Sperling, R.; Selkoe, D.; Weiner, H.L. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J. Clin. Invest., 2003, 112(3), 415-22.
71. Das, P.; Chapoval, S.; Howard, V.; David, C.S.; Golde, T.E. Immune responses against Abeta1-42 in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies. Neurobiol. Aging, 2003, 24, 969-76.
72. Alexander, J.; Sidney, J.; Southwood, S.; Ruppert, J.; Oseroff, C.; Maewal, A.; Snoke, K.; Serra, H.M.; Kubo, R.T.; Sette, A. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity, 1994, 1, 751-61.
73. Alexander, J.; Fikes, J.; Hoffman, S.; Franke, E.; Sacci, J.; Appella, E.; Chisari, F.V.; Guidotti, L.G.; Chesnut, R.W.; Livingston, B.; Sette, A. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol. Res., 1998, 18, 79-92.
74. del Guercio, M.F.; Alexander, J.; Kubo, R.T.; Arrhenius, T.; Maewal, A.; Appella, E.; Hoffman, S.L.; Jones, T.; Valmori, D.; Sakaguchi, K.; Grey, H.M.; Sette, A. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine, 1997, 15, 441-8.
75. Alexander, J.; del Guercio, M.F.; Maewal, A.; Qiao, L.; Fikes, J.; Chesnut, R.W.; Paulson, J.; Bundle, D.R.; DeFrees, S.; Sette, A. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J. Immunol., 2000, 164, 1625-33.
76. La Rosa, C.; Wang, Z.; Brewer, J.C.; Lacey, S.F.; Villacres, M.C.; Sharan, R.; Krishnan, R.; Crooks, M.; Markel, S.; Maas, R.; Diamond, D.J. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood 2002, 100, 3681-9.
77. Wei, W.Z.; Ratner, S.; Shibuya, T.; Yoo, G.; Jani, A. Foreign antigenic peptides delivered to the tumor as targets of cytotoxic T cells. J. Immunol. Methods, 2001, 258, 141-50.
78. Weber, J.S.; Hua, F.L.; Spears, L.; Marty, V.; Kuniyoshi, C.; Celis, E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J. Immunother., 1999, 22, 431-40.
79. Panina-Bordignon, P.; Tan, A.; Termijtelen, A.; Demotz, S.; Corradin, G.; Lanzavecchia, A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol., 1989, 19, 2237-42.
80. Tam, J.P. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. USA, 1988, 85, 5409-13.
81. Agadjanyan, M.G.; Ghochikyan, A.; Petrushina, I.; Vasilevko, V.; Movsesyan, N.; Mkrtichyan, M.; Saing, T.; Cribbs, D.H. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol., 2005, 174, 1580-6.
82. Moore, A.; McCarthy, L.; Mills, K.H. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine, 1999, 17, 2517-27.
83. Maier, M.; Seabrook, T.J.; Lazo, N.D.; Jiang, L.; Das, P.; Janus, C.; Lemere, C.A. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J. Neurosci., 2006, 26, 4717-28.
84. Zou, J.; Yao, Z.; Zhang, G.; Wang, H.; Xu, J.; Yew, D.T.; Forster, E.L. Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response. J. Neurol. Sci., 2008, 272, 87-98.
85. Kim, H.D.; Jin, J.J.; Maxwell, J.A.; Fukuchi, K. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol. Lett., 2007, 112, 30-8.
86. Zamora, E.; Handisurya, A.; Shafti-Keramat, S.; Borchelt, D.; Rudow, G.; Conant, K.; Cox, C.; Troncoso, J.C.; Kirnbauer, R. Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. J. Immunol., 2006, 177, 2662-70.
87. Chackerian, B.; Rangel, M.; Hunter, Z.; Peabody, D.S. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. Vaccine, 2006, 24, 6321-31.
88. Staufenbiel, M.; Wiederhold, K.-H.; Tissot, A.C.; Frey, P.; Fulurija, A.; Hiestand, P.; Jennings, G.T.; Luond, R.; Mayer, P.; Ortmann, R. Immunization with Abeta1-6 coupled to the viral-like particle Qbeta (CAD106) efficiently removes beta-amyloid without inducing Abeta-reactive T cells. Proceedings of 10th ICAD Alzheimer's and Dementia. 2006; p. S20.
89. Jennings, G.T.; Bachmann, M.F. The coming of age of virus-like particle vaccines. Biol. Chem., 2008, 389, 521-36.
90. Nardin, E.H.; Calvo-Calle, J.M.; Oliveira, G.A.; Clavijo, P.; Nussenzweig, R.; Simon, R.; Zeng, W.; Rose, K. Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein. Vaccine, 1998, 16, 590-600.
91. Ghochikyan, A.; Mkrtichyan, M.; Petrushina, I.; Movsesyan, N.; Karapetyan, A.; Cribbs, D.H.; Agadjanyan, M.G. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine, 2006, 24, 2275-82.
92. Donnelly, J.J.; Liu, M.A.; Ulmer, J.B. Antigen presentation and DNA vaccines. Am. J. Respir. Crit. Care Med., 2000, 162, S190-3.
93. Tang, D.C.; Devit, M.; Johnston, S.A. Genetic immunization is a simple method for eliciting an immune response. Nature, 1992, 356, 152-4.
94. Agadjanyan, M.G.; Ugen, K.; Wang, B.; Villafana, T.; Merva, M.; Petrushina, I.; Williams, W.W.; Weiner, D.B. In DNA inoculation with an HTLV-I envelope DNA construct elicits immune responses in rabbits, Chanock, R.M.; Ginsberg, H.S.; Brown, F.; Lerner, R.A., Eds.; Vaccines '94: Modern Approaches to New Vaccines Including Prevention of AIDS. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1994, pp. 47-53.
95. Pardoll, D.M.; Beckerleg, A.M. Exposing the immunology of naked DNA vaccines. Immunity, 1995, 3, 165-9.
96. Wang, B.; Ugen, K.E.; Srikantan, V.; Agadjanyan, M.G.; Dang, K.; Refaeli, Y.; Sato, A.I.; Boyer, J.; Williams, W.V.; Weiner, D.B. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA, 1993, 90, 4156-60.
97. Lu, S.; Arthos, J.; Montefiori, D.C.; Yasutomi, Y.; Manson, K.; Mustafa, F.; Johnson, E.; Santoro, J.C.; Wissink, J.; Mullins, J.I.; Haynes, J.R.; Letvin, N.L.; Wyand, M.; Robinson, H.L. Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol., 1996, 70, 3978-91.
98. Boyer, J.D.; Ugen, K.E.; Wang, B.; Agadjanyan, M.; Gilbert, L.; Bagarazzi, M.L.; Chattergoon, M.; Frost, P.; Javadian, A.; Williams, W.V.; Refaeli, Y.; Ciccarelli, R.B.; McCallus, D.; Coney, L.; Weiner, D.B. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination [see comments]. Nat. Med., 1997, 3, 526-32.
99. Petrushina, I.; Ghochikyan, A.; Mktrichyan, M.; Mamikonyan, G.; Movsesyan, N.; Davtyan, H.; Patel, A.; Head, E.; Cribbs, D.H.; Agadjanyan, M.G. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric A{beta} species in amyloid precursor protein transgenic mice. J. Neurosci., 2007, 27, 12721-31.
100. Movsesyan, N.; Ghochikyan, A.; Mkrtichyan, M.; Petrushina, I.; Davtyan, H.; Olkhanud, P.B.; Head, E.; Biragyn, A.; Cribbs, D.H.; Agadjanyan, M.G. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine-a novel immunotherapeutic strategy. PLos ONE, 2008, 3, e21-4.
101. Bonecchi, R.; Bianchi, G.; Bordignon, P.P.; D'Ambrosio, D.; Lang, R.; Borsatti, A.; Sozzani, S.; Allavena, P.; Gray, P.A.; Mantovani, A.; Sinigaglia, F. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med., 1998, 187, 129-34.
102. Sallusto, F.; Lenig, D.; Mackay, C.R.; Lanzavecchia, A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med., 1998, 187, 875-83.
103. Imai, T.; Nagira, M.; Takagi, S.; Kakizaki, M.; Nishimura, M.; Wang, J.; Gray, P.W.; Matsushima, K.; Yoshie, O. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int. Immunol., 1999, 11, 81-8.
104. Biragyn, A.; Belyakov, I.M.; Chow, Y.H.; Dimitrov, D.S.; Berzofsky, J.A.; Kwak, L.W. DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood, 2002, 100, 1153-9.
105. Haass, C.; Selkoe, D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol., 2007, 8, 101-12.
106. Candore, G.; Balistreri, C.R.; Colonna-Romano, G.; Grimaldi, M.P.; Lio, D.; Listi, F.; Scola, L.; Vasto, S.; Caruso, C. Immunosenescence and antiimmunosenescence therapies: the case of probiotics. Rejuvenation Res., 2008, 11, 425-32.
107. Weinberger, B.; Herndler-Brandstetter, D.; Schwanninger, A.; Weiskopf, D.; Grubeck-Loebenstein, B. Biology of immune responses to vaccines in elderly persons. Clin. Infect. Dis., 2008, 46, 1078-84.
108. Franceschi, C.; Olivieri, F.; Marchegiani, F.; Cardelli, M.; Cavallone, L.; Capri, M.; Salvioli, S.; Valensin, S.; De Benedictis, G.; Di Iorio, A.; Caruso, C.; Paolisso, G.; Monti, D. Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech. Ageing Dev., 2005, 126, 351-61.